Acute kidney injury after cardiac surgery: prevalence, impact and management challenges

M Vives1
A Hernandez2
F Parramon3
N Estanyol3
B Pardina3
A Muñoz2
P Alvarez4
C Hernandez3

1Department of Anesthesiology & Critical Care, Clinical Research Lead, Hospital Universitari Dr Josep Trueta, Universitat de Girona, Institut d’Investigació Biomédica de Girona (IDIBGI), Girona, Spain; 2Department of Anesthesiology & Critical Care, Grupo Policlínica, Ibiza, Spain; 3Department of Anesthesiology & Critical Care Chief, Hospital Universitari Dr Josep Trueta, Universitat de Girona, Girona, Spain; 4Department of Cardiac Surgery, Hospital Universitari Dr Josep Trueta, Universitat de Girona, Girona, Spain

Abstract: Acute kidney injury (AKI) is a major medical problem that is of particular concern after cardiac surgery. Perioperative AKI is independently associated with an increase in short-term morbidity, costs of treatment, and long-term mortality. In this review, we explore the definition of cardiac surgery-associated acute kidney injury (CSA-AKI) and identify diverse mechanisms and risk factors contributing to the renal insult. Current theories of the pathophysiology of CSA-AKI and description of its clinical course will be addressed in this review. Data on the most promising renal protective strategies in cardiac surgery, from well-designed studies, will be scrutinized. Furthermore, diagnostic tools such as novel biomarkers of AKI and their potential utility will be discussed.

Keywords: cardiac surgery, acute renal failure, acute kidney injury, prevention, therapy

Introduction

Acute kidney injury (AKI) after cardiac surgery occurs from a rapid deterioration in renal function following cardiac surgery expressed as a significant decrease in glomerular filtration rate (GFR). The reported prevalence of cardiosurgery-associated acute kidney injury (CSA-AKI) is up to 30%1 and is independently associated with an increase of morbidity and mortality. When CSA-AKI is defined in its most severe form as requiring dialysis, the prevalence is usually low, occurring up to 4%.2-4 With milder degrees of renal dysfunction, the incidence shows a wide variation in the reported literature. Even a small increase (0.3–0.5 mg/dL) in serum creatinine (sCr) after cardiac surgery may be independently associated with a significant increase in 30-day mortality.5 While mortality after open-heart surgery with no AKI, ranges between 1% and 8%, the odds of death increases more than fourfold.6 The need of renal replacement therapy (RRT) has been associated with an increase in mortality, up to 63%.7 CSA-AKI is the most common cause of AKI in intensive care unit (ICU) after sepsis.8 Regardless of whether there is a complete renal recovery or not, the 10-year mortality associated with AKI after cardiac surgery is still increased.9 In this narrative review article, pathogenesis, definition, risk prediction, early detection by biomarkers, promising prevention and treatment strategies for AKI after cardiac surgery will be discussed.

Defining acute kidney injury

More than 30 different definitions for ARF have been used in the past. The new diagnostic scales use variations in sCr values and urinary output to define the presence and severity of ARF and have been validated by numerous studies. In...
2004, the risk-injury-failure-loss-end-stage kidney disease (RIFLE) definition by the Acute Dialysis Quality Initiative Group was introduced. The dysfunction criteria were based on a relative rise in sCr, the absolute level of urine output, or both. In 2007, the Acute Kidney Injury Network (AKIN) proposed a modification of the RIFLE classification. It occurred when the impact of small elevations of sCr on mortality (>0.3 mg/dL [>26 mmol/L]) was reported. This scale defines AKI as an abrupt reduction (within 48 hrs) of renal function with an absolute increase in sCr (≥0.3 mg/dL [≥26.4 mmol/L] or ≥50% [1.5 times compared to baseline]), or a reduction in urine output <0.5 mL/kg/hr for >6 consecutive hours. The application of AKIN and RIFLE criteria following cardiac surgery without correcting for sCr changes owing to fluid balance leads to AKI under-diagnosis. The Kidney Disease: Improving Global Outcomes (KDIGO) definition of AKI was associated with a higher sensitivity to diagnose AKI and to predict in-hospital mortality, compared to RIFLE or AKIN. The KDIGO definition, which is a combination of the RIFLE and AKIN classification, is the most commonly used definition for CSA-AKI. However, the main limitation of these definitions is that they rely on sCr, which is known to be affected by factors not-GFR related, including age, sex, race, body surface area, diet, diabetes, liver disease, different drugs and laboratory analytical methods. Furthermore, using sCr it is unknown whether the origin of the injury is tubular or glomerular. The three main definitions of AKI are slightly different. Therefore, using different definitions may lead to differences on the prevalence and prognosis of AKI after cardiac surgery. Criteria for the diagnosis of AKI are shown in Table 1.

Pathogenesis of acute kidney injury after cardiac surgery

The pathophysiology of AKI after cardiac surgery is complex and multifactorial. The following mechanisms of injury might be involved: microembolization, neurohormonal activation, exogenous and endogenous toxins, metabolic as well as hemodynamic and inflammation factors, ischemia–reperfusion injury and oxidative stress. These mechanisms of injury may be interrelated and synergistic. The consequence of these insults is a cascade of reflex changes within the kidney leading to a common presentation of AKI manifesting as impairment of renal function, persistent renal vasoconstriction, an exaggerated response to exogenous vasoconstrictors, and vascular endothelial and tubular epithelial cell death due to necrosis and apoptosis.

Common nephrotoxic agents are antibiotics, such as glycopeptides and aminoglycosides, and non-steroidal anti-inflammatory agents. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) may cause renal efferent arteriolar vasodilation and its use is associated with AKI.

Regional blood flow and renal vasomotor tone are altered by the use of cardiopulmonary bypass (CPB). Furthermore, systemic inflammatory response is activated, and microemboli may be generated, associated with the use of CPB. The systemic inflammatory response is activated mainly due to the direct contact of blood with the artificial surface of the bypass circuit.

The use of CPB has been associated with an alteration of vasomotor tone and a reduction in the renal parenchymal oxygen tension, and consequently, decreasing the renal perfusion pressure up to 30% and, hence, increasing the ischemia–reperfusion injury.

The formation of microemboli may be increased by the use of CPB. It is well known that emboli smaller than 40 μm are not effectively filtered by CPB-system filters and can damage renal capillaries directly.

The release of free hemoglobin secondary to hemolysis is associated with renal tubular damage as well as increased systemic vascular resistance, platelets and coagulation activity dysfunction and increased mortality. A summary of the different and complex pathophysiologic mechanisms is shown in Figure 1.

Risk factors and prediction of acute kidney injury after cardiac surgery

A plethora of risk factors have been identified over the last 45 years since the first report of ARF after cardiac surgery. AKI following cardiac surgery is the net result of several perioperative insults, some or all of which may occur in any given patient. Based on the current literature, the following risk factors are independently associated with AKI after cardiac surgery: i) elderly and female sex, ii) preoperative cardiac dysfunction (preoperative use of an intra-aortic balloon pump, New York Heart Association IV, cardiogenic shock, reduced left ventricular ejection fraction (LVEF), congestive heart failure), iii) emergent surgery, iv) peripheral arterial disease, v) reintervention, vi) insulin-requiring diabetes, vii) preoperative renal dysfunction [estimated glomerular filtration rate (eGFR) <60 mL/min, creatinine >2.1 mg/dL], viii)
COPD, intraoperative use of aprotinin. The risk factor preoperative renal dysfunction is the most predictive for AKI after cardiac surgery. Other risk factors described are related to the type of cardiac surgical procedure, regardless of bypass time. Patients undergoing valvular surgery, with or without coronary artery bypass graft (CABG) are at a greater risk for the development of AKI compared with those undergoing CABG alone. Furthermore, cross-clamp time and duration of CPB are important risk factor for CSA-AKI. Therefore, any adverse event during surgery causing longer cross-clamp time or bleeding will lead to an increased rate of AKI. Other important risk factors include

<table>
<thead>
<tr>
<th>Grade I</th>
<th>Grade II</th>
<th>Grade III</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIFLE score</td>
<td>Increase creatinine x1.5 or GFR decreases &gt;25% from baseline in 7 days or UO &lt;0.5 mL/kg/hr for 6–12 hrs</td>
<td>Increase creatinine x2–2.9 or GFR decreases &gt;50% from baseline in 7 days or UO &lt;0.5 mL/kg/hr for &gt;12 hrs</td>
</tr>
<tr>
<td>AKIN score</td>
<td>Increase creatinine x1.5 or by ≥0.3 mg/dL (≥26.5 μmol/L) from baseline in 48 hrs or UO &lt;0.5 mL/kg/hr for 6–12 hrs</td>
<td>Increase creatinine x2–2.9 in 7 days from baseline or UO &lt;0.5 mL/kg/hr for &gt;12 hrs</td>
</tr>
<tr>
<td>KDIGO score</td>
<td>Increase creatinine by ≥0.3 mg/dL (≥26.5 μmol/L) in 48 hrs, or increase creatinine x1.5–1.9 from baseline within 7 days or UO &lt;0.5 mL/kg/hr for 6–12 hrs</td>
<td>Increase creatinine x2–2.9 in 7 days from baseline or UO &lt;0.5 mL/kg/hr for &gt;12 hrs</td>
</tr>
</tbody>
</table>

**Abbreviations:** RIFLE, risk-injury-failure-loss-end-stage kidney disease; AKIN, Acute Kidney Injury Network; KDIGO, Kidney Disease: Improving Global Outcomes; GFR, glomerular filtration rate; RRT, renal replacement therapy; UO, urine output.

**Figure 1** Summary of the different and complex pathophysiologic mechanisms.
transfusion of red blood cells (RBC) and haemodilution during CPB. Furthermore, preoperative anemia, defined as hemoglobin <12.5 mg/dL, is associated with an increased risk of AKI after cardiac surgery, regardless of intraoperative RBC transfusion.22

Early identification of patients at high risk of AKI after cardiac surgery using risk scores enables clinicians to initiate early preventive and therapeutic strategies to reduce the risk of AKI. Several risk scores to predict AKI have been developed, but no guidelines exist to recommend the use of a specific prediction model. The Cleveland Clinic score,4 the Mehta score,3 and the Simplified Renal Index (SRI) score2 have been used for predicting the need for dialysis initiation (c-statistics 0.75–0.79). However, their performance for predicting non-RRT AKI is generally poor (c-statistics 0.54–0.59).23 Among the prediction rules for AKI requiring dialysis after cardiac surgery, the Cleveland score has been the most widely tested thus far and has shown high discrimination in most of the tested populations.2,24,25 Mehta Score is not as easy to use than the SRI score and Cleveland score. Therefore, given its simplicity, the SRI score and the Cleveland score are the most commonly used in clinical practice. Moreover, the Cleveland score showed good performance to predict a composite end-point of severe AKI (defined as SCR rise >2.0 mg/dL or a twofold increase from preoperative values) in a cohort from the Mayo Clinic.25 New scores for predicting AKI after cardiac surgery, including intraoperative factors, have been recently published. The use of these new scores improves performance when compared with the previous scores.26,27

The main disadvantage of the modified Cleveland score is the large amount of variables included and the difficulty in calculating the score.

A summary assessing the predictive ability of different risk scores is shown in Table 2.

**Prognosis of acute kidney injury after cardiac surgery**

The long-term consequences of AKI after cardiac surgery might be development of chronic kidney disease, increased mortality, reduced quality of life and increased risk of cardiovascular events.

Mortality after severe AKI requiring RRT was 52.6% at 60 days and 44.7% at 90 days in the RENAL study.28

Data from a retrospective study showed a 30-day mortality rate of 58.6% for patients with AKI requiring RRT after cardiac surgery.29

In the ATN study, which included patients undergoing cardiac surgery, complete recovery of kidney function (defined as sCr level ≤0.5 mg/dL (44 μmol/L) above the baseline value) by 28 days after randomization was seen in 16.9% of patients. Partial recovery (defined as a sCr level that remained at >0.5 mg/dL above baseline in patients who were not dependent on dialysis) was seen in 8.9% of patients. In the RENAL study, which also included patients undergoing cardiac surgery, 13.3% of patients were dependent on RRT at 28 days and 5.6% at 90 days after randomization. However, no specific data on renal recovery for patients undergoing cardiac surgery were provided in the RENAL trial.

Data from a meta-analysis on 35,021 patients in nine observational studies show a higher long-term mortality risk in those patients who have a persistent renal dysfunction compared to those who have a recovery of renal function to baseline levels before hospital discharge (HR 2.71, 95% CI 1.26–5.82).30

An important factor determining the prognosis of AKI after cardiac surgery is the duration of AKI. Data from an observational study on 4,987 patients showed that a duration of 7 days or longer were associated with both increased inhospital mortality (15.3% vs 4.1%) and 5-year mortality (HR 3.40 vs 1.66) compared to AKI lasting 1–2 days.31 Data from a retrospective study on 10,275 consecutive patients showed that early renal recovery seems to offer a distinct survival benefit. The most significant predictor of 1-year survival is the percent decrease of sCr within 24 hr of its peak.32

**Renal protective strategies**

Currently, there is no pharmacological intervention that has consistently been associated with renal protection. This failure is likely related to the following reasons: i) AKI after cardiac surgery is pathophysiologically multifactorial and complex, thus simple strategies targeting single pathways will most likely fail, ii) strategies guided by creatinine rise will be initiated too late and consequently, they will also, most likely, fail, iii) most data come from clinical trials not enrolling a large sample size on low-risk patient population with lower prevalence of AKI. Therefore, most of them are inadequately powered to detect small benefits.

**Preoperative strategies**

Delaying elective surgery for renal function optimization in patients with reversible AKI should be considered. Preoperative decisions regarding chronic medication may influence perioperative renal risk. Renal function optimization
<table>
<thead>
<tr>
<th>Variable</th>
<th>Cleveland score&lt;sup&gt;4&lt;/sup&gt;</th>
<th>Metha score&lt;sup&gt;3&lt;/sup&gt;</th>
<th>SRI&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Modif Cleveland&lt;sup&gt;16&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Definition - Score</td>
<td>Definition - Score</td>
<td>Definition - Score</td>
<td>Definition - Score</td>
</tr>
<tr>
<td>Age</td>
<td>Varies - varies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Race</td>
<td>Non-White - 2</td>
<td></td>
<td>White</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Black</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Another</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>Female - 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td>Varies - varies</td>
</tr>
<tr>
<td>Preoperative Renal function</td>
<td>sCr 1.2-2.1 - 1</td>
<td>sCr varies</td>
<td>eGFR 31–60 - 1</td>
<td>eGFR - varies</td>
</tr>
<tr>
<td></td>
<td>sCr &gt;2.1 - 5</td>
<td></td>
<td>eGFR &lt;31 - 2</td>
<td></td>
</tr>
<tr>
<td>Preoperative Albumin</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative Sodium</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative Bicarbonate</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative sUrea Nitrogen</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative Hemoglobin</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative platelet</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preoperative Bilirubin</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHF</td>
<td>Yes - 1</td>
<td></td>
<td></td>
<td>Varies - varies</td>
</tr>
<tr>
<td>HTN</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td>Requiring medication - 1</td>
<td>Varies - varies</td>
</tr>
<tr>
<td>COPD</td>
<td>Yes - 1</td>
<td>Yes - 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary Disease</td>
<td></td>
<td>Varies - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recent MI (&lt;21 days)</td>
<td>Yes - 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVEF</td>
<td>&lt;35% - 1</td>
<td>&lt;40% - 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous surgery</td>
<td>Yes - 1</td>
<td>Yes - 3</td>
<td>Yes - 1</td>
<td></td>
</tr>
<tr>
<td>Previous IABP</td>
<td>Yes - 2</td>
<td></td>
<td>Yes - 1</td>
<td></td>
</tr>
<tr>
<td>Cardiogenic Shock</td>
<td>Yes - 7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Timing of surgery</td>
<td>Emergence - 2</td>
<td>Non-elective - 1</td>
<td>Emergence - varies</td>
<td></td>
</tr>
<tr>
<td>CPB time</td>
<td></td>
<td>&lt;80 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>81–120 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>121–150 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>151–180 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;180 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraop PRBC</td>
<td></td>
<td>None - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1–2 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3–4 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>5–6 - varies</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>&gt;6 - varies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
A decrease of hemodilution - III trial showed no difference in primary outcome (a composite outcome of any cause-mortality, stroke, new-onset AKI requiring dialysis or myocardial infarction) comparing hemoglobin 7.5 g/dL vs 9.5 g/dL as a trigger for transfusion of RBC intraoperatively. 

It is reasonable to use preoperative erythropoietin (EPO) plus iron (especially if ferritin is <100 mg/L), given several days before surgery, in patients with preoperative anemia (Hb <12.5 g/dL) and patients who refuse transfusion, such as Jehovah’s Witness. However, chronic use of EPO is associated with thrombotic cardiovascular events in chronic kidney disease patients suggesting caution with the use of EPO in patients with unstable symptoms undergoing CABG surgery.

**Intraoperative strategies**

Preoperative as well as intraoperative anemia have been shown to be independently associated with AKI after cardiac surgery. However, it is also well known that intraoperative RBC transfusion is associated with a higher rate of AKI after cardiac surgery. 

Data from Toronto General Hospital database suggest that the change of hemoglobin from its baseline is more important than its absolute value. A decrease of hemoglobin of >50% from baseline, significantly increase the risk of AKI. Moreover, recent data from a Spanish multicenter cohort suggest that not only the change from baseline is important, but also the duration of anemia. A perioperative hemoglobin area under the curve (pHbAUC) of <19 g/dL showed a higher association with AKI after cardiac surgery, compared to a single preoperative or intraoperative value of hemoglobin.

2011 STS/SCA blood conservation guidelines suggest that transfusion to keep hemoglobin >7 g/dL while on CPB, on patients at risk for end-organ ischemia or injury, may be considered (IIb). TRICS-III trial showed no difference in primary outcome (a composite outcome of any cause-mortality, stroke, new-onset AKI requiring dialysis or myocardial infarction) comparing hemoglobin 7.5 g/dL vs 9.5 g/dL as a trigger for transfusion of RBC intraoperatively and postoperatively in the ICU.

The initiation of a program on blood management decreases the rate of RBC, platelets and FFP transfusion as well as the rate of AKI (34% relative risk reduction; P=0.039) and the associated healthcare cost. This program consists of transfusion thromboelastography-guided, preoperative anemia optimization, restrictive threshold for intraoperative transfusion, retrograde autologous priming.

### Table 2 (Continued).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Cleveland score</th>
<th>Metha score</th>
<th>SRI</th>
<th>Modif Cleveland</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Definition - Score</td>
<td>Definition - Score</td>
<td>Definition - Score</td>
<td>Definition - Score</td>
</tr>
<tr>
<td>Intraop vasopressors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intraop UO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type of surgery</td>
<td>CABG only - 0</td>
<td>CABG only - 0</td>
<td>Other than isolated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Valve only - 1</td>
<td>Aortic Valve only - 2</td>
<td>CABG or ASD repair - 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CABG + Valve - 2</td>
<td>AV + CABG - 5</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mitral Valve only - 4</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>MV + CABG - 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Score range</td>
<td>0–17</td>
<td>0–83</td>
<td>0–8</td>
<td>0–100</td>
</tr>
</tbody>
</table>

**Note:** In Thakar score, sCr <1.2 mg/dL and isolated CABG are considered as reference (0 points). In SRI score, an eGFR >60 mL/min and isolated CABG and correction of atrial septal defects are taken as reference (0 points).

**Abbreviations:** AKI, acute kidney injury; ASD, Atrial septal defect; BMI, body mass index; CABG, coronary artery bypass graft; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CPB, Cardio-pulmonary Bypass; eGFR, estimated GFR; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction; sCr, serum creatinine; sUrea, serum urea; recent MI, recent myocardial infarction; UO, urine output.
reduced volume of the bypass circuit and increase use of cell saver and tranexamic acid.\textsuperscript{44}

Despite new technologies, CPB is still contributing to the development of AKI after cardiac surgery. Modifying CPB strategies aimed at decreasing the renal effects have been investigated. Based on current data, use of mini-CBP may be considered,\textsuperscript{45,46} and zero-balanced ultrafiltration during CPB, especially for patients with eGFR <60, may be considered.\textsuperscript{47} Flow during CPB, rather than pressure, may be the important determinant of renal function. One of the main goals, if not the greatest, when conducting CPB is the delivery of oxygen to the tissues.

A goal-directed perfusion initiative aiming for oxygen delivery (DO2) >300 mL with mean arterial pressure >70 mmHg during CPB plus zero-balanced ultrafiltration, was associated with a significant reduction of AKI at 72 hrs (23.9% vs 9.1%).\textsuperscript{48} Hence, based on current data, MAP >70 mmHg and DO2 >300 mL O\textsubscript{2}/min/m during CPB should be considered.

Hyperglycemia (>180 mg/dL) should be avoided during the perioperative period, with caution to avoid hypoglycemia also. The most important factor is to avoid large glucose variability throughout the entire perioperative time frame.\textsuperscript{49,50}

Regarding the use of balanced hydroxyethyl starch (HES) 130/0.4 in cardiac surgery, data from two recent clinical trials in the context of critically ill patient population show that the use of HES increased the risk for the need of dialysis initiation.\textsuperscript{51,52} Furthermore, the 6S trial which focused on patients with severe sepsis found an 8% higher 90-day mortality associated with the use of HES.\textsuperscript{52} However, routine cardiac surgery patients were not included in these trials. Septic patient population differs from routine cardiac surgery patients. Vascular endothelium is differently affected,\textsuperscript{53} and therefore, large molecules are distributed differently.\textsuperscript{54}

Data on the use of balanced HES 130/0.4 in cardiac surgery patients are limited. Data from a prospective multicenter cohort on 1,058 patients showed that the use of modern starch 6% HES 130/0.4 was not associated with a higher rate of AKI and dialysis after cardiac surgery.\textsuperscript{55} However, only 10% of this cohort presented with chronic kidney disease. Therefore, in author’s opinion, modern starch 6% HES 130/0.4 may be used in patients with normal renal function undergoing cardiac surgery.

**Surgical strategies**

The CORONARY trial found that there was no difference between off-pump and on-pump CABG, in terms of RRT requirement [HR, 1.04 (0.61–1.76), \( P=0.59 \)]. However, the use of off-pump CABG was associated with a lower rate of mild AKI, defined by AKIN stage 1 [HR 0.87 (0.80–0.96), \( P=0.01 \)] or RIFLE-risk [HR 0.87 (0.76–0.98), \( P=0.02 \)]. In the CORONARY trial, the lack of definition for initiation of RRT leads to possible different managements in the same clinical scenario. No differences were found at 1 year and at 5 years in the CORONARY trial follow-up. Unfortunately, mild AKI was not analyzed.\textsuperscript{56,57}

However, data from 5-year follow-up of the Veterans Affairs trial of on-pump versus off-pump CABG showed that off-pump CABG led to lower rates of 5-year survival and event-free survival than on-pump CABG.\textsuperscript{58} Consequently, the greater operative safety and possible prevention of AKI with OPCAB may come at the expense of long-term survival gains.

Catheter-based minimally invasive surgery, on the other hand, has been consistently associated with improved renal outcome, particularly in mitral valve surgery.\textsuperscript{59,60} Endovascular repair of aortic pathology may be beneficial with regard to postoperative renal function in comparison with open procedures.\textsuperscript{61}

**Pharmacological renal protection**

Many drugs aiming for preventing the AKI after cardiac surgery have been studied. Up to date, none of them have conclusively showed to decrease the prevalence of AKI after cardiac surgery. However, some of them appeared promising: amino acids, dexmedetomidine and vasopressin.

Acute increases in overall amino acids blood concentration can be induced by a protein meal as well as intravenously infused amino acids.\textsuperscript{62} Amino acids affect the kidney through several mechanisms. First, their infusion in laboratory rats increases nephrin plasma flow by decreasing afferent arteriolar resistance.\textsuperscript{63} This effect appears mediated by reductions in signaling molecules of the tubule-glomerular feedback system, mitigating arteriolar constriction,\textsuperscript{64} or by increases in neuronal nitric oxide synthase in the kidney cortex, reducing afferent arteriolar tone.\textsuperscript{65} Second, in other animal models, high-protein diets, through vascular endothelial growth factor, lead to an increase in size and volume of glomeruli.\textsuperscript{66} Third, infused amino acids are filtered by the glomerulus and act directly on the kidney, stimulating proximal tubular sodium reabsorption, and may change the sensitivity of the macula densa sensing mechanism by altering cell permeability. Fourth, reduced tubular sodium chloride concentration induces release of endothelial growth factor and prostaglandins locally from the macula densa cells,
which impairs voltage-dependent calcium channels in the smooth muscle cell membrane, resulting in afferent arteriolar vasodilatation. These effects provide the biologic rationale that infused amino acids may improve renal outcomes through increased renal plasma flow and an associated increase in GFR. Evidence from a randomized clinical trial published in the New England Journal of Medicine and including 53 critically ill patients demonstrated that a short-term infusion of amino acids led to faster recovery from severe acute renal failure. Moreover, a 2007 clinical trial demonstrated that patients randomized to receive short-term higher dose of intravenous amino acids were more likely to maintain diuresis and less furosemide to achieve a negative fluid balance were required. A RCT with 3,500 patients undergoing cardiac surgery testing the hypothesis of kidney protection by an amino acid infusion is underway (NCT037909264).

There has been some controversy regarding the best type of anesthesia used in cardiac surgery. A meta-analysis on 1,600 patients from 10 RCT shows that volatile anesthesia is associated with a decrease risk of AKI (RR 0.65; 0.43–0.97, P=0.04), compared to TIVA. Volatiles have a known effect of ischemic/reperfusion injury attenuation. Hence, based on current data, use of volatile anesthetics should be considered.

The renal RIP trial showed a significant reduction on the incidence of major adverse kidney events at 90 days (death, RRT and persistent renal dysfunction) – 14.2% vs 25%, P<0.034, associated with the use of remote ischemic preconditioning (rIPC) in high-risk patients with Cleveland score ≥6. Moreover, AKI patients in rIPC group recover faster. They observed that the effect of rIPC is attenuated by propofol. Hence, based on current data, use of rIPC in high-risk patients with Cleveland score ≥6, without using propofol, may be considered.

The LICRA trial on 1,136 patients showed no differences in AKI – KDIGO II and III at 5 days, comparing 0.9% saline with buffered salt solution. However, in our opinion, given the existing data showing increase risk of AKI with 0.9% saline in ICU patients, balanced crystalloid solutions should be used, unless hypotremia is present.

It has been suggested that the use of fenoldopam, a selective dopamine receptor-1 agonist, might be associated with a lower rate of AKI after cardiac surgery. Unfortunately, a definitive recent multicenter RCT on 667 patients was stopped for futility in the interim analysis.

Natriuretic peptide may induce natriuresis and vasodilatation by opposing the RAAS and vasopressin system. Several multicenter trials and meta-analyses show benefit by decreasing RRT and AKI. Data from 7 systematic reviews showed a significant decrease of RRT rate associated with atrial NP (NNT=22) and cerebral NP (NNT=11), with no effect on mortality. Hence, based on current data, use of natriuretic peptide, especially in high-risk patients, may be considered.

It has been suggested that the use of sodium bicarbonate might be renoprotective. A higher tubular pH could be protective by inhibiting the hydroxyl radical generation and lipid peroxidation. A multicentre RCT on 427 patients in 2013 was negative. More recently, a meta-analysis of 3 RCT, on 877 patients, observed a benefit in a sub-group analysis on patients undergoing CABG (adjusted OR for RRT 0.38 (0.25–0.58) and adjusted OR for AKIN grade 3 is 0.45 (0.43–0.48)). However, imbalances in prognostically important characteristics were observed. Hence, based on present data, prophylactic use of bicarbonate should not be considered.

Levosimendan has predominant renal afferent vasodilatation, rather than efferent. It has been suggested that its use might be renoprotective. A metanalysis on 1,345 patients from 13 RCT, in which 87.5% have LVEF ≤40%, showed a reduction of AKI rate (OR 0.51, 95% CI 0.34–0.76) and AKI requiring RRT (OR 0.43, 95% CI 0.25–0.76), associated with the use of levosimendan. A recent meta-analysis on 2,243 patients from 14 RCT, which included 2 recent large RCT, showed that patients receiving levosimendan were less likely to die at 30 days (RR =0.71, 95% CI=0.53–0.95; P=0.023). It is suggested that this benefit may be limited to patients with low to moderate ejection fraction (RR=0.44, 95% CI=0.27–0.70; P<0.001), with no benefit for patients with preserved ejection fraction (RR=1.06, 95% CI=0.72–1.56; P=0.78). Patients receiving levosimendan were also less likely to require RRT (RR=0.66, 95% CI=0.47–0.92; P=0.015) and to have a low cardiac output syndrome (RR=0.40, 95% CI=0.22–0.73; P=0.003).

An updated 2017 expert opinion of the working group in AKI prevention from the European Society of Intensive Care Medicine, recommend against the use of levosimendan for renal protection in cardiac surgery patients with poor preoperative left ventricular function or needing postoperative hemodynamic support (Grade 1B). However, unpublished data from a subgroup analysis of all the patients undergoing CABG with LVEF <40% in the LEVO-CTS and the LICORN trial, presented at the 2018 European Association of Cardiothoracic Anesthesia
(EACTA) meeting, showed a decreased risk of mortality at 1 and 3 months, associated with the use of levosimendan compared to placebo (7.7% vs 2.9%, OR 0.36, 95% CI 0.18–0.72). Based on current data, levosimendan still may have a role if used for CABG patients with LVEF <40%.83

Dexmedetomidine is a highly selective alpha-2 agonist with short half-life. Ratio of alpha-2 to alpha-1 is 1,600:1; inhibits renin release and attenuates sympathetic activity and vasoconstriction. It causes sympathetic stabilization, anti-inflammatory effect and ischemic/reperfusion injury attenuation. Data from an RCT on 200 patients showed a significant AKI reduction rate (14% vs 33%) associated with dexmedetomidine compared to placebo.84 A retrospective single-center on 1,133 patients, using propensity score matching and logistic regression, observed an association between dexmedetomidine and a decrease in AKI rate (26.1% vs 33.75%; adjusted OR 0.7; 95% CI 0.54–0.91, P=0.008).

Vasopressin binds to AVPR1a to promote vasoconstriction through several pathways, including modulation of ATP-sensitive K+ channel function and nitric oxide production and enhancement of the vascular response to catecholamines. Since vasopressin acts on renal efferent arterioles, as opposed to noradrenaline which acts mainly on the renal afferent arteriole, might have nephroprotective effects. A single double-blind RCT on 330 patients on vasoplegic shock after cardiac surgery showed a lower composite primary endpoint (30-day mortality or stroke, AKI, Mech Vent >48 hrs, reoperation), with the use of vasopressin – 32% vs 49%, P=0.0014 – compared to norepinephrine. Use of vasopressin was also associated with less AKI (10.3% vs 35.8%, adjusted OR 0.26, 95% CI 0.15–0.46, P<0.0001), less AF with vasopressin (63.8% vs 82.1%; P=0.0004), no difference in digital or mesenteric ischemia and myocardial infarction.85 Hence, based on current data, use of vasopressin to protect the kidney in patients with vasoplegic syndrome after cardiac surgery should be considered.

**Postoperative strategies**

Based on current data, it is reasonable to maintain hemoglobin of >8 mg/dL during the postoperative period. The recent TITRe2 trial showed no differences in primary outcome at 3 months using postoperative hemoglobin of 7.5 vs 9 as a transfusion trigger for transfusion.86

Data from an RCT on 276 in high-risk patients showed that KDIGO bundle decrease AKI rate in high-risk patients undergoing cardiac surgery, defined by biomarkers, as urinary [TIMP-2]-[IGFBP7] >0.3. AKI defined by KDIGO 1 or worse at 72 hrs postoperatively (71% vs 55%, OR 0.48; 95% CI 0.29–0.79). KDIGO bundle consist of avoiding ACEi/ARB first 48 hrs postoperatively, avoiding hyperglycemia first 72 hrs postoperatively, using alternatives to radiocontrast agents and lastly optimizing hemodynamics guided by PiCCO first 48 hrs (consequently, more dobutamine and similar amount of fluid was used, compared to standard of care).87

The early use of RRT after cardiac surgery has been suggested to be associated with improved in-hospital survival in patients with CSA-AKI. Data from a meta-analysis on 847 patients, including 2 RCT and 9 observational cohorts, showed a decrease of 28-day mortality associated with use of early RRT after cardiac surgery (OR 0.29, 95% CI 0.16–0.52, P<0.0001).88

The ELAIN trial, a recent well-designed single center RCT on 231 patients (50% of them were post-cardiac surgery patients), showed that early use of RRT (within 8 hrs of diagnosis of KDIGO stage 2) was associated with a decrease in 90-day mortality (39.3% vs 54.7%), a decrease in RRT duration, mechanical ventilation time and length of hospital stay and increase rate of renal recovery by day 90 (53.6% vs 38.7%), compared to late use of RRT after cardiac surgery (within 12 hrs of AKIN stage 3).89 Therefore, based on current data, use of early RRT should be considered.

KDIGO guidelines suggest the use of continuous RRT in unstable patients (grade 2B). However, extended daily dialysis (EDD) may also be suitable for the treatment in this setting. EDD provides hemodynamic tolerability and is significantly cheaper. No difference in renal function, mortality, renal recovery and hospital stay has been shown. Hemodynamic measurements, including heart rate, systolic blood pressure and diastolic blood pressure were comparable.90

The 20th International Consensus Conference of the ADQI (Acute Disease Quality Initiative) Group on Cardiac and Vascular Surgery-Associated Acute Kidney Injury suggests the following recommendations:91

1. Avoidance of glucose variability (1B)
2. Balanced crystalloid (vs saline) (1B)
3. Use of dexmedetomidine (2C)
4. Limited use of blood transfusion (1A)
5. Discontinuation of ACEIs and ARBs (1C)
6. Albumin in off-pump CABG patients with hypoalbuminemia (2C)
7. 24-hr to 72-hr delay post-contrast before cardiac surgery (2C)
8. Pre-operative IABP in high-risk cardiac surgery patients (2C)
9. Volatile anesthetic agents (vs propofol) (2C)
10. Avoidance of hyperthermia (2C)
11. Pulsatile CPB in high-risk patients (2D)
12. Avoidance of hemodilution (2C)
13. Remote ischemic preconditioning in high-risk patients (2B)
14. KDIGO bundle in high-risk patients (1B)
15. We recommend not using natriuretic peptide, fenoldopam, diuretics, dopamine, or mannitol for the treatment of AKI after cardiac surgery (grade 1C).
16. The decision to start RRT should be individualized with consideration of the clinical context and not be based solely on renal function or stage of AKI. Once the decision to initiate RRT has been made, it should be started promptly (not graded).

The updated 2017 expert opinion of the working group on prevention, AKI section, from the European Society of Intensive Care Medicine, suggests the following recommendations regarding kidney protection during cardiac surgery:\(^\text{92}\)

A summary of all measures for preventing AKI after cardiac surgery can be found in Table 3.

### Early detection of acute kidney injury: the role of new biomarkers

RIFLE, AKIN and KDIGO definitions have an important prognostic impact.\(^\text{92}\) However, they are based on sCr, and its use may delay the diagnosis of AKI for 24–72 hrs, compared to new biomarkers. This could be explained by its late increase. The loss of half of the renal function is required in order for the sCr to increase. Therefore, it may take days to increase. Several other factors may affect the concentration of sCr.\(^\text{15}\)

The combination of two tubular stress biomarkers – insulin-like growth factor-binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases-2 (TIMP-2) – is very promising for early detection of tubular damage. Recent data show that these two biomarkers combined may diagnose AKI in a very early phase.

Data from a prospective cohort study on 150 patients showed an independent association between [TIMP-2*IGFBP7] at ICU admission and postoperative AKI at 48 hrs (OR 11.83; \(P<0.001\), aROC=0.74) after logistic regression adjusting for EuroSCORE II and CPB-time.\(^\text{93}\) A recent meta-analysis, with 10 prospective cohorts studies on 747 patients undergoing cardiac surgery, published from 2014 to 2017, showed an aROC of 0.83, indicating high predictive accuracy.\(^\text{94}\) Based on current data, the combination of these two tubular stress biomarkers (Nephrocheck®), IGFBP7 plus TIMP-2, is the most promising biomarkers for early diagnosis of AKI after cardiac surgery.

Patients with an early higher urinary and plasma NGAL levels are most likely to be diagnosed of AKI (aROC 0.78).\(^\text{95}\) Therefore, NGAL levels may detect AKI 24–72 hrs earlier than sCr. Furthermore, NGAL has also prognostic impact. Whether other confounding factors may affect NGAL is still unknown.

<table>
<thead>
<tr>
<th>Preoperative strategies</th>
<th>Intraoperative strategies</th>
<th>Postoperative strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>-General measures: avoid intravascular volume depletion, optimize cardiac output, avoid nephrotoxic drugs</td>
<td>-Zero-balanced ultrafiltration during CPB for patients with eGFR &lt;60(^\text{97})</td>
<td>-Keep Hb &gt;8 mg/dL(^\text{16})</td>
</tr>
<tr>
<td>-Aspirin(^\text{33,34})</td>
<td>-DO2 &gt;300 ml with MAP &gt;70 mmHg during CPB(^\text{48})</td>
<td>-Use of early RRT(^\text{88,89})</td>
</tr>
<tr>
<td>-Statins continuation(^\text{39})</td>
<td>-Avoid RBC unless Hb &lt;7 g/dl(^\text{42})</td>
<td>-Avoid ACEI/ARB(^\text{87})</td>
</tr>
<tr>
<td>-Iron if Hb &lt;12.5 and ferritin is &lt;100 mg/L</td>
<td>-Volatile anesthesia(^\text{69})</td>
<td>-Avoid nephrotoxic drugs</td>
</tr>
<tr>
<td>-Using exogenous albumin to correct hypalbuminemia (level of &lt;4 g/dl) in off-pump CABG surgery(^\text{15,36})</td>
<td>-Avoid glycermia &gt;180 mg/dl and large glucose variability(^\text{49,50})</td>
<td>-Use of dexmedetomidine(^\text{84})</td>
</tr>
<tr>
<td>-Program on blood management (TEG-guided transfusion, cell saver and use of tranexamic acid)(^\text{84})</td>
<td>-rIPC in patients with Cleveland score ≥ 6, with no use of propofol(^\text{70,71})</td>
<td>-Avoid glycermia &gt;180 mg/dl and large glucose variability(^\text{49,50})</td>
</tr>
<tr>
<td>-rIPC in patients with Cleveland score ≥ 6</td>
<td>-Levosimendan for CABG if LVEF &lt;40%</td>
<td>-To optimize hemodynamics individually guided by transpulmonary thermodilution first 2 days(^\text{87})</td>
</tr>
</tbody>
</table>

| Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CPB, cardio-pulmonary bypass; DO2, oxygen delivery; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; LVEF, left ventricle ejection fraction; RBC, red blood cells; RRT, renal replacement therapy; TEG, thromboelastography. |

---

The decision to start RRT should be individualized with consideration of the clinical context and not be based solely on renal function or stage of AKI. Once the decision to initiate RRT has been made, it should be started promptly (not graded).

---

**Table 3** Summary of all measures that might protect the kidney in cardiac surgery
Data from a meta-analysis on 2,322 patients suffering from AKI related to cardiac disease, suggest that patients with a higher NGAL, are most likely to develop adverse outcomes, even when sCr is normal. Hence, it is suggested that subclinical AKI may be diagnosed by this biomarker.\(^{96}\) However, several issues should be clarified before using NGAL routinely in clinical practice, mainly a large variability in its predictive capacity (aROC) as shown in published data.\(^{97-99}\)

Predictive capacity of several other biomarkers has been studied (Table 4). Cystatin C is a potential marker of GFR. It also appears to be independent of age, sex and lean muscle mass. Because of controversial results in early studies, its predictive capacity and prognostic impact in AKI after cardiac surgery needs to be further studied.\(^{100}\)

Acute tubular injury is associated with an increase in urinary IL-18. Given that urinary IL-18 levels have a stronger association with CPB time rather than AKI itself, it is suggested that urinary IL-18 levels are more a marker of inflammation rather than a marker of kidney injury in patients undergoing cardiac surgery.\(^{100}\)

The use of a combination of several markers has been suggested to improve diagnostic performance of AKI after cardiac surgery. Data from a prospective observational study on 77 patients suggest that a combination of urinary biomarkers is associated with a higher discriminatory capacity, compared to a single biomarker (aROC 0.81 vs aROC 0.75 for NAG alone or aROC 0.72 for L-FABP alone).\(^{101}\) Furthermore, the inclusion of a combination of biomarkers to clinical factors was associated with an improvement in diagnostic performance, compared to clinical factors alone (aROC 0.86 vs 0.79).

Data from a prospective cohort on 380 patients showed that biomarkers may predict worsening of AKI after cardiac surgery.\(^{102}\) Biomarkers also improved predictive performance, compared to clinical factors alone. Included biomarkers were urinary IL-18, urinary albumin to creatinine ratio and urinary and plasma NGAL.

Stress biomarkers are promising tools for early diagnosis of AKI after cardiac surgery. However, important issues need to be better understood before using these biomarkers in our clinical practice. These issues include, first, the large variations in diagnostic performance reported. Second, factors not kidney-related affecting individual biomarkers are not well understood. Lastly, data reporting the diagnostic performance of biomarkers, excluded patients with chronic kidney disease, which are high-risk group of patients for developing renal injury after cardiac surgery. Based on current data, however, the most promising biomarker for early prediction of CSA-AKI is the combination of two tubular stress biomarkers (urinary IGFBP7 and TIMP-2 levels) measured at ICU admission.\(^{94}\)

**Conclusion**

AKI after cardiac surgery is independently associated with a significant increase in morbidity, mortality and healthcare costs.

Kidney protection strategies to prevent AKI after cardiac surgery are not yet conclusive. These strategies include delaying elective surgery to enable full kidney function optimization, individualized hemodynamic optimization by the use of inotropics or fluid therapy and judicious use of RBC.

Prolonged aortic cross-clamping, intravascular hemolysis or contrast dye exposure should be avoided.

The current most promising pharmacological prevention strategies are dexmedetomidine, vasopressin and amino acids, but much more data are needed.

**Table 4 New biomarkers for detecting AKI post injury after cardiac surgery**

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Sample source</th>
<th>Features</th>
<th>Heart surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>NGAL</td>
<td>Urine and plasma</td>
<td>It is filtered freely by the glomerulus; It is reabsorbed in the DT</td>
<td>Increase 2 hrs post-CPB</td>
</tr>
<tr>
<td>IL-18</td>
<td>Urine</td>
<td>Proinflammatory cytokine produced after the injury of the epithelial cells of DT</td>
<td>Increase 4–6 hrs post-CPB</td>
</tr>
<tr>
<td>KIM-1</td>
<td>Urine</td>
<td>Transmembrane glycoprotein expressed after the injury of the epithelial cells of DT</td>
<td>Increase 12–24 hrs post-CPB</td>
</tr>
<tr>
<td>L-FABP</td>
<td>Urine</td>
<td>Cytosol protein synthesized in the liver</td>
<td>Increase 4 hrs post-CPB</td>
</tr>
<tr>
<td>Cystatin C</td>
<td>Urine and plasma</td>
<td>It filters freely through the glomerulus without reabsorbing</td>
<td>Increase 12 hrs post-CPB</td>
</tr>
</tbody>
</table>

Abbreviations: CPB, cardio-pulmonary bypass; DT, distal tubule; NGAL, neutrophil gelatinase-associated lipocalin; IL-18, interleukin 18; KIM-1, kidney injury molecule-1; L-FABP, liver-type fatty acid-binding protein.
As the knowledge of the pathophysiology of AKI after cardiac surgery improves, our aim of preventing and treating as early as possible, will be also improved.

Finally, early treatment by RRT of patients early diagnosed by a combination of biomarkers may improve outcomes.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


